You are here

Our science / Clinical Trials / Find a Trial / NCT00945555

Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options

Back to Search Print Save as PDF Bookmark Trial

NCT00945555

Last updated on December 6, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Ankara, , 06500 Turkey
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Febrile Neutropenia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients who are 18 years old and above.

- Patients who have undergone allogeneic/autologous or peripheral stem cell
transplantation following induction or consolidation treatment due to acute
hematological malignancy.

- Patients who have a neutrophil count below 500 cells per cubic millimeter (cells/mm^3)
or below 1000 cells/mm^3 with an expectancy to rapidly decrease below 500 cells/mm^3.

- Patients with a body temperature more than or equal to (≥)38.3 degrees Celsius (101
degrees Fahrenheit) on single oral measurement or detected ≥38.0 degrees Celsius for
at least an hour and thus started on antibacterial treatment will be included in the
trial.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who are pregnant or considering pregnancy.

NCT00945555
Pfizer
Completed
Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Neutropenia
A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants
NCT02629289
All Genders
18+
Years
Adelaide, South Australia
Febrile Neutropenia
Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options
NCT00945555
All Genders
18+
Years
Multiple Sites
Chemotherapy-Induced Neutropenia
Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study
NCT02454530
All Genders
18+
Years
Multiple Sites
Neutropenia (Low White Blood Cell Count)
A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)
NCT02766634
All Genders
18+
Years
Multiple Sites
Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options
Multi-Center, Non-Interventional, Observational Study To Evaluate The Antibacterial Therapeutical Options In Febrile Neutropenia Patients
The purpose of this study was to define and classify antibacterial agents used in Turkey for patients with febrile neutropenia.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with febrile neutropenia who were planning to take antibacterial treatment.
Febrile Neutropenia
Drug: Antibacterial agent for the treatment of febrile neutropenia
The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
All participants
Participants with febrile neutropenia who received antibacterial treatment per investigator's judgment
Intervention: Drug: Antibacterial agent for the treatment of febrile neutropenia
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
264
October 2010
October 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who are 18 years old and above.
  • Patients who have undergone allogeneic/autologous or peripheral stem cell transplantation following induction or consolidation treatment due to acute hematological malignancy.
  • Patients who have a neutrophil count below 500 cells per cubic millimeter (cells/mm^3) or below 1000 cells/mm^3 with an expectancy to rapidly decrease below 500 cells/mm^3.
  • Patients with a body temperature more than or equal to (?)38.3 degrees Celsius (101 degrees Fahrenheit) on single oral measurement or detected ?38.0 degrees Celsius for at least an hour and thus started on antibacterial treatment will be included in the trial.

Exclusion Criteria:

- Patients who are pregnant or considering pregnancy.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Turkey
 
 
NCT00945555
A1891006
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now